ArticleJournal of neurochemistry2025
Metabolic Profiling Reveals a Glycolytic Shift and an IRG1/Itaconate/NF2L2 Axis Regulating Neurotoxic Oxidative Stress in Inflammatory Microglia.
Article in Journal of neurochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Crosstalk Between Nrf2 and Metabolic Pathways: Redox Regulation, Glutaminolysis, and Cellular Proliferation.Cell biochemistry and biophysics · 2026Review
- Immunometabolic reprogramming in multiple sclerosis: from pathogenic amplifier to therapeutic target in neuroinflammation and remyelination.Inflammopharmacology · 2026Review
- Metabolic Reprogramming of Brain Microglia: Implications for Aging and Aging-Associated Neurodegenerative Diseases.Aging cell · 2026Review
- Metabolic control of neuroinflammation: focus on itaconate and its derivatives in CNS disorders.Frontiers in immunology · 2026Review
- ACOD1 regulates microglial arginine metabolism and inflammatory responses.Frontiers in immunology · 2026Article
- Metabolic Profiling Reveals a Glycolytic Shift and an IRG1/Itaconate/NF2L2 Axis Regulating Neurotoxic Oxidative Stress in Inflammatory Microglia.Journal of neurochemistry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Polar metabolic profiling, as well as bioenergetic assays, were used to characterize microglial responses to lipopolysaccharide, which induces a pro-inflammatory state, and interleukin-4, which is associated with an anti-inflammatory phenotype. BV2 microglial cells and primary microglia were used for these investigations. Results revealed that lipopolysaccharide-treated microglia exhibited an increased aerobic glycolytic activity measured by extracellular flux analysis, accompanied by increased levels of endogenous itaconate, a metabolite produced by the IRG1 enzyme. Increased itaconate levels observed by LC-HRMS were found to be associated with a stabilization of the NF2L2/NRF2 transcription factor. Attenuation of the Acod1 gene leads to increased pro-inflammatory cytokine production, as measured by ELISA, while having no effect on LPS-induced oxidative stress or neurotoxicity, an effect only observed upon silencing Nfe2l2. This suggests that an IRG1/itaconate/NRF2 axis functions as a feedback mechanism. The study underscores the dual role of metabolic reprogramming in microglial activation, balancing inflammation and neuroprotection, and suggests potential therapeutic targets for neuroinflammatory diseases by modulating itaconate and NF2L2/NRF2-related pathways. This work highlights the complexity and therapeutic potential of targeting microglial metabolism in CNS disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.